Type 2 Diabetes Clinical Trial
Official title:
Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).
Evidence shows independent associations between elevated serum uric acid (sUA) and the risk
of hypertension, myocardial infarction (MI), chronic kidney disease (CKD), T2DM, heart
failure (HF), and metabolic syndrome, including obesity. Gout is associated with an increased
risk of all-cause death, as well as cardiovascular death. The causal relationship between
elevated sUA, gout, and these disease outcomes remains to be proven.
Verinurad (RDEA3170), is a novel Urate Transporter 1 (URAT1) inhibitor in Phase II
development. Verinurad combined with the xanthine oxidase (XO) inhibitor febuxostat has been
shown to lower sUA in patients with recurrent gout in Phase II studies by >80%. The extensive
lowering of sUA delivered by the combination presents a unique opportunity to explore whether
intensive urate lowering therapy can improve kidney and/or cardiac health.
This study will assess if intensive serum urate lowering therapy, more potent than ever
explored before in the chronic out-patient setting, can improve chronic kidney or cardiac
function in the study population.
In order to maximize the scientific value of the study and minimize the risk for systemic
biases a parallel group, double blind, randomized design will be utilized.
The study will recruit patients with hyperuricemia and presenting with albuminuria.
Hyperuricemic patients are expected to benefit more from urate lowering, and albuminuria at
baseline is required, as the primary objective of the study will be to assess changes in
albuminuria.
Patients are also required to be diagnosed with T2DM. Patients with T2DM frequently exhibit
changes in cardiac function detectable using magnetic resonance imaging (MRI) that represents
an early, pre-symptomatic state of HF. By limiting recruitment to patients with T2DM and by
performing MRI at baseline and 6 months of therapy, the study will deliver insights into
whether or not intensive urate lowering therapy can positively affect not only chronic kidney
disease, but also cardiac disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |